Note the wording in the release. This announcement relates to RVX -208. Therefore it will be subject to the same royalty agreement on the RPS held by Zenith. BUT the release also talks about the results of additional pre-clinical testing on OTHER BET inhibitors in the RVX library. So RVX appears to be planning to advance other molecules for other indications. This means RVX will no longer be considered a 'one-trick pony'. we are moving in the direction of multiple drugs/molecules and multiple indications.